Teclistamab 153mg/1.7mL Injection$4,700.00
1–9 boxes
$4,700.00 each
10–24 boxes
8% off
25+ boxes
10% off
Teclistamab 153mg/1.7mL Injection
SKU GME1107Oncology Care
Product Introduction
Teclistamab 153mg/1.7mL is a bispecific-antibody treatment for multiple myeloma that has returned or no longer responds to previous therapies. It brings immune T cells into contact with abnormal plasma cells so they can attack the myeloma.
How to use
A trained healthcare professional injects the medicine under the skin of the abdomen or thigh. Treatment starts with smaller step-up doses, premedication and close observation around the early injections. This 153mg/1.7mL vial contains 90mg/mL and differs from the lower-concentration vial used for step-up dosing.
How it works
Teclistamab binds BCMA on myeloma cells and CD3 on T cells. Bringing these cells together activates T cells to attack the myeloma cells.
Side effects
Fever, injection-site reactions, fatigue, low blood counts and infections are common. Cytokine release syndrome can cause fever, low blood pressure and breathing problems. Confusion, altered speech, tremor or seizures can signal neurological toxicity and require urgent treatment.
Important information
Infection prevention, blood counts and immunoglobulin levels are important throughout treatment. Hepatitis B status and vaccination history are assessed before starting. Live vaccines are avoided, and new infections may require an injection delay. The early-dose observation schedule is an essential part of treatment.
Uses
- Relapsed or refractory multiple myeloma within an appropriate regimen after previous myeloma treatment, including proteasome-inhibitor, immunomodulatory and anti-CD38 exposure where applicable.
Benefits
Redirecting T cells offers another treatment mechanism when myeloma has returned or stopped responding to earlier therapies. Responses are followed using myeloma-protein measurements, blood results and other disease assessments.
Is teclistamab a CAR-T treatment?
No. It is a bispecific antibody given by injection. It recruits existing T cells without collecting and genetically modifying the patient's cells.
Why are the first injections smaller?
Step-up dosing introduces immune activation gradually to reduce the risk and severity of cytokine release syndrome. These initial doses are not interchangeable with the full treatment dose.
Why can immunoglobulin replacement become necessary?
Treatment can lower normal antibody levels as well as affect abnormal plasma cells. If antibody deficiency and infection risk become significant, immunoglobulin replacement may form part of supportive care.
Can a normal temperature rule out a treatment complication?
No. New confusion, speech changes, severe weakness or breathing difficulty still needs urgent assessment, even without fever, because neurological or infectious complications may present differently.
BCMA: protein expressed on plasma cells. CD3: T-cell protein targeted to activate immune attack. Bispecific antibody: antibody binding two different targets. CRS: cytokine release syndrome. ICANS: immune effector cell-associated neurotoxicity syndrome. Immunoglobulin: infection-fighting antibody.; AR: Teclistamab 153mg/1.7mL حقن; FR: Teclistamab 153mg/1.7mL préparation injectable; PT: Teclistamab 153mg/1.7mL injetável; ES: Teclistamab 153mg/1.7mL inyectable; RU: Teclistamab 153mg/1.7mL инъекционная форма; ID: Teclistamab 153mg/1.7mL injeksi; VI: Teclistamab 153mg/1.7mL thuốc tiêm; MS: Teclistamab 153mg/1.7mL suntikan; TL: Teclistamab 153mg/1.7mL iniksyon; ZH-SG: Teclistamab 153mg/1.7mL 注射剂